Andrew S. Herbert

This study identifies phosphatidylserine receptors as critical for CCHFV infection and shows that targeting these receptors can protect against viral disease.

This study identifies key glycoprotein residues that enhance the efficacy of a CCHFV vaccine by modulating cleavage and fusogenicity in animal models.

This study identifies GP38 as a viral toxin causing vascular leak and shows that specific GP38-targeting antibodies block this effect in vitro and in vivo.

The paper describes the structure and immunogenicity of a stabilized CCHFV heterotrimeric glycoprotein complex and shows it provides 40% protection against viral challenge in mice.

The paper identifies non-neutralizing antibodies from CCHFV survivors that target multiple regions on GP38, showing protective efficacy in rodent models.

The paper identifies SARS-CoV-2 neutralizing antibodies from convalescent patients and describes a novel quaternary binding mechanism using high-throughput methods.